Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT06583291
EARLY_PHASE1
iDAP Injection in the Treatment of Parkinson's Disease
Sponsor: Anhui Provincial Hospital
View on ClinicalTrials.gov
Summary
The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy that iDAP has on Parkinson's disease (PD) patients.
Official title: A Single Center, Open-label Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Allogeneic Dopaminergic Neural Precursor Cell(iDAP) Injection in the Treatment of Parkinson's Disease
Key Details
Gender
All
Age Range
45 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2024-10-01
Completion Date
2028-10-01
Last Updated
2024-09-04
Healthy Volunteers
No
Conditions
Interventions
DRUG
Allogeneic dopaminergic neural precursor cell(iDAP)
Bilateral implantation